Over the years, PharmaMar has received numerous awards that recognize the efforts of the Company since its inception to advance cancer research and innovation in the marine biomedical space. The company has been honored with awards that show our commitment with our people, social responsibility, creativity and innovation.

The Company has been rated “excellent”, once again, in the call 2014 of the Profarma program, an initiative of the Ministry of Industry, Energy and Tourism to enhance the competitiveness of the pharmaceutical sector. This qualification has been maintained for more than 10 years

leyenda_premios_ENG_v02
Plan PROFARMA Award for Excellence
in Biotechnological R&D and Innovation
Ministry of Industry, Energy and Tourism 2015

Program which aims to enhance the competitiveness of the pharmaceutical sector that gives companies a rating based on their activities and investments in areas such as technology applied to production or R & D + i.

XIV AECA Award for Business Transparency Ministry of Industry, Energy and Tourism 2015

The Prize recognizes the efforts and results of the Spanish companies in terms of information transparency.

ASPID Award for international campaign to
relaunch Yondelis® in ovarian-cancer DLP®
ASPID 2013

The ASPID awards selects projects in the fields of communication, advertising and marketing that stand out for their creativity.

National Innovation and Design Award for internationalization 2011 General Secretariat of Science, Technology and Innovation 2011

The award honors the companies that have a significative turnover abroad in relation to their total turnover and take part in numerous european and national R&D projects.

The Elsevier Galien Award to Yondelis® for “Best Pharmaceutical Product of the Year” ELSERVIER GALIEN 2009

Awards presented annually by the Elsevier group in recognition of excellence and commitment on the part of public and private institutions for the benefit of research and health.

RX Silver Award RX Club Show Prizes of New York 2008

The award was given to PharmarMar for its campaign “Yondelis® redesign the future of Soft Tissue Sarcoma (STS)”. This award is one of the health communication competition’s most prestigious, whose selection criteria are based, exclusively, on the creative concept and execution.

The Elsevier Galien Award for Excellence in Biotechnological R&D ELSERVIER-GALIEN 2008

Awards presented annually by the Elsevier group in recognition of excellence and commitment on the part of public and private institutions for the benefit of research and health.

Sarcoma Foundation of America Award for Commitment
to Research into Soft Tissue Sarcoma
SARCOMA FOUNDATION OF AMERICA 2008

The “Supporting a Cure in our Time” Award given by the Sarcoma Foundation of America (SFA) is awarded to PharmaMar for its “support to the search for an effective cure for soft tissue sarcomas”, which is the objective of the foundation.

FundaMed-El Global Award to the Career
of Jose María Fernández Sousa-Faro
FUNDAMED 2008

The prize is awarded by Fundamed together with the Global weekly. The award honors those who through their careers have contributed to improving the health system and the population health.

Oncology pipeline

PharmaMar develops and commercializes YONDELIS® in Europe and has three clinical-stage drug candidates under development for several types of solid and hematological cancers, Aplidin ®, Lurbinectedin, and PM184.

Other Businesses

PharmaMar’s core business is oncology and it fully owns other companies that cover different aspects of healthcare and consumer chemical products.

Our History

Zeltia was founded in 1939. Since then, the Company has achieved several milestones in the field of the chemical and biopharmaceutical sectors. Of note, the authorization of the first marine-derived anticancer drug.